- Raised $30M funding round, Oct 2018
- Raised $5M funding round, Nov 2020
About
Breath of Life (BOL) Pharma is developing cannabinoid-based drugs to improve patients' health and quality of life with high-quality botanical-derived products. BOL Pharma cultivates and farms its own proprietary cannabis strains, has state-of-the-art certified labs, and owns a plant and a distribution center.
BOL Pharma addresses the medical cannabis, wellness, and pharmaceutical markets. The pharmaceutical division has launched a spinoff company, with an inhaler based on a Kindeva drug delivery platform (formerly 3M DDS) for selected pain indications as its core product.
This pressurized metered dose inhaler (pMDI) contains cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) for multiple sclerosis-related neuropathic pain (lead indication). Additional follow-on planned indications include chemotherapy-induced and HIV-induced neuropathic pain.
The cannabinoid-based pMDI is a combination product of drug/drug/device and offers an efficient administration route of delivery compared to oral delivery. Inhalation of THC/CBD avoids irregular gastrointestinal absorption and first-pass hepatic metabolism. This leads to increased bioavailability and improved pharmacokinetics of THC/CBD (reduction in inactive circulating metabolites, larger fraction of active parent THC/CBD). It also delivers a rapid, consistent, reproducible dose, and is safe (inhalation may reduce hepatoxicity concerns, as lung absorption bypasses first-pass hepatic metabolism) and easy to use (breath actuated, no special preparation required). The technology is based on a pharmaceutically well-known inhaler device and is environmentally friendly, using low global-warming-potential propellants. The IP-protected device (with additional IP generated during clinical development) addresses the need for non-opioid analgesics, with a quick onset of action.
Funding history · 2 rounds · $35.0M total
Q&A
- What is the current operational status of Breath of Life Pharma?
- Breath of Life Pharma is currently inactive, having ceased operations in April 2025.
- What is Breath of Life Pharma's primary focus?
- Breath of Life Pharma focuses on developing cannabinoid-based drugs and products, including an inhaler for pain indications, and cultivates its own proprietary cannabis strains.
- What is the total amount of funding raised by Breath of Life Pharma?
- Breath of Life Pharma has raised a total of $35,000,000 USD.
- When was Breath of Life Pharma's last funding round and who participated?
- Breath of Life Pharma's last funding round was in November 2020, raising $5,000,000 USD with participation from OurCrowd.
- What was the largest funding round for Breath of Life Pharma and who were the investors?
- In October 2018, Breath of Life Pharma raised $30,000,000 USD. Investors included Gandyr Investments and OurCrowd.
- How many employees does Breath of Life Pharma have?
- Breath of Life Pharma has 11-50 employees.
- What is the core product of Breath of Life Pharma's pharmaceutical division?
- The pharmaceutical division of Breath of Life Pharma has launched a spinoff company with a pressurized metered dose inhaler (pMDI) based on a Kindeva drug delivery platform, containing CBD and THC for multiple sclerosis-related neuropathic pain.
- In which markets does Breath of Life Pharma operate?
- Breath of Life Pharma addresses the medical cannabis, wellness, and pharmaceutical markets.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/27171274 |
Identifiers & details
| Founded | 2007-1 |
|---|---|
| Employees (exact) | 37 |
| Status reason | Non Active, Apr 2025 ceased to operate |